• Apple, Inc AAPL
  • S&P 500 ETF Trust SPDR SPY
  • Alphabet Inc. - Class A Shares GOOGL
  • Microsoft Corporation MSFT
  • Meta Platforms Inc META
  • Netflix, Inc. NFLX
  • Amazon.com Inc. AMZN
  • Spotify Technology SA SPOT
    crsp-img

    Crispr Therapeutics AG, Common Stock

    CRSP

    NMQ

    $56.22

    +$0.55

    (0.99%)

    1D
    Industry: Biotechnology Sector: Health Care

    Analyst Forecast

    Overview Returns Financials Ratios News FAQs

    Price Chart

    Key Metrics

    Market Cap info-icon
    This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
     $4.77B
    P/E Ratio info-icon
    This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
     NM
    Volume info-icon
    This is the total number of shares traded during the most recent trading day.
     1.08M
    Avg Volume info-icon
    This is the average number of shares traded during the most recent 30 days.
     1.44M
    Dividend Yield info-icon
    This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
     0.00%
    Beta info-icon
    This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
     1.79
    52-week Range info-icon
    This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
    $37.55 L
    $91.1 H
    $56.22

    About Crispr Therapeutics AG, Common Stock

    CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, immune-oncology and autoimmune, in vivo, and type 1 diabetes. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease, and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting CD19 and CTX131 targeting CD70 for oncology and autoimmunune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and VCTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland. more

    Industry: BiotechnologySector: Health Care

    Returns

    Time FrameCRSPSectorS&P500
    1-Week Return9.87%1.89%1.51%
    1-Month Return1.19%5.68%5.65%
    3-Month Return-28.59%1.18%6.8%
    6-Month Return-17.19%15.01%18.16%
    1-Year Return-12.72%13.5%29.33%
    3-Year Return-48.53%24.42%33.21%
    5-Year Return44.78%80.35%100.99%
    10-Year Return299.01%193.83%237.54%

    Financials

    Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
    Total Revenue289.59M543.00K913.08M436.00K370.00M[{"date":"2019-12-31","value":31.72,"profit":true},{"date":"2020-12-31","value":0.06,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":0.05,"profit":true},{"date":"2023-12-31","value":40.52,"profit":true}]
    Cost of Revenue179.36M269.41M101.18M110.25M130.25M[{"date":"2019-12-31","value":66.58,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":37.56,"profit":true},{"date":"2022-12-31","value":40.92,"profit":true},{"date":"2023-12-31","value":48.35,"profit":true}]
    Gross Profit289.59M(268.86M)913.08M(109.81M)239.75M[{"date":"2019-12-31","value":31.72,"profit":true},{"date":"2020-12-31","value":-29.45,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-12.03,"profit":false},{"date":"2023-12-31","value":26.26,"profit":true}]
    Gross Margin100.00%(49514.55%)100.00%(25186.70%)64.80%[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-49514.55,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-25186.7,"profit":false},{"date":"2023-12-31","value":64.8,"profit":true}]
    Operating Expenses242.85M354.98M539.55M563.35M462.29M[{"date":"2019-12-31","value":43.11,"profit":true},{"date":"2020-12-31","value":63.01,"profit":true},{"date":"2021-12-31","value":95.78,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":82.06,"profit":true}]
    Operating Income46.74M(354.44M)373.53M(673.16M)(222.54M)[{"date":"2019-12-31","value":12.51,"profit":true},{"date":"2020-12-31","value":-94.89,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-180.22,"profit":false},{"date":"2023-12-31","value":-59.58,"profit":false}]
    Total Non-Operating Income/Expense-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
    Pre-Tax Income67.31M(348.06M)379.53M(650.50M)(150.72M)[{"date":"2019-12-31","value":17.73,"profit":true},{"date":"2020-12-31","value":-91.71,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-171.4,"profit":false},{"date":"2023-12-31","value":-39.71,"profit":false}]
    Income Taxes448.00K809.00K1.87M(325.00K)2.89M[{"date":"2019-12-31","value":15.51,"profit":true},{"date":"2020-12-31","value":28.01,"profit":true},{"date":"2021-12-31","value":64.75,"profit":true},{"date":"2022-12-31","value":-11.25,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
    Income After Taxes-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
    Income From Continuous Operations66.86M(348.87M)377.66M(650.17M)(153.61M)[{"date":"2019-12-31","value":17.7,"profit":true},{"date":"2020-12-31","value":-92.38,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-172.16,"profit":false},{"date":"2023-12-31","value":-40.67,"profit":false}]
    Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
    Net Income66.86M(348.87M)377.66M(650.17M)(153.61M)[{"date":"2019-12-31","value":17.7,"profit":true},{"date":"2020-12-31","value":-92.38,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-172.16,"profit":false},{"date":"2023-12-31","value":-40.67,"profit":false}]
    EPS (Diluted)0.97(5.27)4.42(8.37)(1.96)[{"date":"2019-12-31","value":21.95,"profit":true},{"date":"2020-12-31","value":-119.23,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-189.37,"profit":false},{"date":"2023-12-31","value":-44.34,"profit":false}]

    Ratios

    Liquidity

    These ratios help you determine the liquidity of the company. Higher is better.

    CRSP
    Cash Ratio 17.72
    Current Ratio 17.81

    Asset Efficiency

    These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

    CRSP
    ROA (LTM) -7.97%
    ROE (LTM) -11.02%

    Liabilities

    These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

    CRSP
    Debt Ratio Lower is generally better. Negative is bad. 0.15
    Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.85
    Debt/Equity The higher the number, the more leverage the business employs, the riskier the investment typically is. 1.17

    Valuation

    These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

    CRSP
    Trailing PE NM
    Forward PE 23.36
    P/S (TTM) 13.87
    P/B 2.74
    Price/FCF 43
    EV/R 9.99
    EV/Ebitda NM
    PEG NM

    News

    BLUE vs. CRSP: Why Are These Stocks Moving in Opposite Directions?

    Last week, Bluebird Bio (NASDAQ:BLUE) shares climbed while CRISPR Therapeutics (NASDAQ:CRSP) stock fell back. The latter has since spiked, while Bl…

    17 May, 2024 a 4:46 pm TipRanks

    Is CRISPR Therapeutics Stock a Buy?

    The gene-editing therapy specialist is rising in prominence.

    17 May, 2024 a 1:30 pm The Motley Fool

    Wall Street Favorites: 3 Biotech Stocks with Strong Buy Ratings for May 2024

    With innovation, millions of retiring baby boomers, demand for better care, patent cliffs, gene-editing, massive interest in weight-loss treatments, and an increase in mergers, biotech stocks to buy have a good deal of upside ahead. Look at weight loss stocks, like Viking Therapeutics (NASDAQ: VKTX ), for example. Since December, the stock ran from about $12 a share to a recent high of $78.03. All on excitement for its injectable and oral treatments for weight loss, both of which are still in trials. Look at CRISPR Therapeutics (NASDAQ: CRSP ), which ran from about $40 to $90. All thanks to the U.S. FDA’s approval of its treatment for sickle cell disease. Biogen (NASDAQ: BIIB ) exploded from a low of about $190 to a recent high of $235.44. All after the U.S. FDA gave its Eisai (OTCMKTS: ESAIY )-partnered Alzheimer’s treatment a fast-track designation, as noted by Investors’ Business Daily . Even better, there are even more exciting biotech stocks to buy just like these. Here are three you may want to consider today.

    17 May, 2024 a 10:15 am InvestorPlace

    The 3 Best Cathie Wood Stocks to Buy in May 2024

    As investors, we are always aiming to reevaluate our portfolios and make additions. However, we can often get lost in the vastness of the markets when deciding on just a handful of companies. A great place to solve this dilemma is by looking at what other investors are choosing. What better place to start than looking for the best Cathie Wood stocks to buy? After all, she is one of the most famous and respected investors. If she has done the work of rigorously analyzing these companies to put into the holdings of her funds, then they could also be potential new candidates to add into our own portfolios! Now, you might ask why not purchase shares in her different funds? Well, Cathie Wood takes a very risky approach to investing. While she has plenty of great companies in her funds, many are also extremely risky bets. Thus, I have searched deeply through her many holdings to find the best companies that balance growth with risk. As such, here are three of the best stocks to buy with the Cathie Wood seal of approval.

    13 May, 2024 a 10:04 am InvestorPlace

    The 3 Most Undervalued Biotech Stocks to Buy in May 2024

    The biotech sector holds some of the most promising and popular stocks on the market. With the promise of breakthrough treatments that generate billions of dollars annually, investors always look for the next up-and-comer. And within this popular market are stocks that are valued well below their potential. These three biotech stocks have some of the most promising treatments awaiting approval. But they aren’t trading at a value reflective of the likely explosive future growth. Investors should take advantage of the opportunity to buy these stocks at a lower price. Then plan to hold them as massive sales and approvals send their stocks higher and higher. We’ll detail the current valuations of these stocks and the treatments that each has coming down the pipeline. CRISPR Therapeutics (CRSP) Source: rafapress / Shutterstock.com CRISPR Therapeutics (NASDAQ: CRSP ) offers a relatively unique set of treatments specializing in gene editing. The company’s best-selling treatment, Casgevy, targets transfusion-dependent beta-thalassemia and sickle cell disease.

    11 May, 2024 a 2:00 pm InvestorPlace

    Genomics Game-Changers: 3 Stocks Unlocking the Secrets of Life

    Genomics is the future of medicine. With it, companies are racing to shed light on human health and disease. Over the last two decades, related studies have allowed us to create genetic risk scores. For example, millions of people can get a better idea of developing a disease based on individual genetics. Also, this is creating big opportunity for some of the best genomics stock picks. “Genomics has given us a more comprehensive understanding of genetic risk factors for complex traits (body mass index, or BMI, for example) and diseases such as diabetes or asthma,” according to the University of Colorado’s Department of Biomedical Informatics. “We can now calculate genetic risk scores, which are individual-level estimates of the cumulative contribution of genetic factors to a specific trait or disease.” Additionally, genomics could create a potential $157.47 billion market by 2033 from $33.9 billion in 2023, as noted by NovaOneAdvisor.com. And along the way, it could help unlock substantial riches for genomics stock picks.

    10 May, 2024 a 10:00 am InvestorPlace

    Discover more

    Tsla

    Tesla, Inc.
    aaple

    Apple, Inc.
    GOOGL

    Alphabet Inc. - Class A Shares
    META

    Meta Platforms Inc
    AMZN

    Amazon.com Inc.
    Microsoft

    Microsoft Corporation
    NVDA

    NVIDIA Corporation
    BRK

    Berkshire Hathaway Inc. Hld B
    LLY

    Eli Lilly and Company

    FAQs

    What is Crispr Therapeutics AG share price today?

    Crispr Therapeutics AG (CRSP) share price today is $56.22

    Can Indians buy Crispr Therapeutics AG shares?

    Yes, Indians can buy shares of Crispr Therapeutics AG (CRSP) on Vested. To buy Crispr Therapeutics AG from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CRSP stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

    Can Fractional shares of Crispr Therapeutics AG be purchased?

    Yes, you can purchase fractional shares of Crispr Therapeutics AG (CRSP) via the Vested app. You can start investing in Crispr Therapeutics AG (CRSP) with a minimum investment of $1.

    How to invest in Crispr Therapeutics AG shares from India?

    You can invest in shares of Crispr Therapeutics AG (CRSP) via Vested in three simple steps:

    • Click on Sign Up or Invest in CRSP stock at the top of this page
    • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
    • Transfer USD funds to your US Brokerage account and start investing in Crispr Therapeutics AG shares
    What is Crispr Therapeutics AG 52-week high and low stock price?

    The 52-week high price of Crispr Therapeutics AG (CRSP) is $91.1. The 52-week low price of Crispr Therapeutics AG (CRSP) is $37.55.

    What is Crispr Therapeutics AG price-to-earnings (P/E) ratio?

    The price-to-earnings (P/E) ratio of Crispr Therapeutics AG (CRSP) is NM

    What is Crispr Therapeutics AG price-to-book (P/B) ratio?

    The price-to-book (P/B) ratio of Crispr Therapeutics AG (CRSP) is 2.74

    What is Crispr Therapeutics AG dividend yield?

    The dividend yield of Crispr Therapeutics AG (CRSP) is 0.00%

    What is the Market Cap of Crispr Therapeutics AG?

    The market capitalization of Crispr Therapeutics AG (CRSP) is $4.77B

    What is Crispr Therapeutics AG’s stock symbol?

    The stock symbol (or ticker) of Crispr Therapeutics AG is CRSP

    Feedback

    Signup to access all features and start your US investing journey!

    • Open your account in minutes
    • Take your portfolio global, starting at just $1
    Get started

    Add ticker to compare

    white-logo

    222 N. Sepulveda Blvd, Suite 10-124, 
El Segundo, CA 90245, USA

    5 Vivekanand Villa, 139 S V Road, Andheri West, Mumbai, Mumbai City, Maharashtra, India, 400058

    help@vestedfinance.co | +919513375607

    Google_Play_Store
    Apple_store
    instagram twitter linkedin

    Company

    Explore Products

    MOST POPULAR ON VESTED

    Popular US Stocks 1

    Apple Microsoft Alphabet (Google) Amazon NVIDIA Meta Platforms (Facebook) Berkshire Hathaway Tesla Eli Lilly Visa UnitedHealth Walmart JPMorgan Chase Exxon Mobil Broadcom Johnson & Johnson Mastercard Procter & Gamble Oracle Home Depot Chevron Adobe Merck Costco AbbVie

    Popular US ETFs 2

    SPDR S&P 500 ETF Trust iShares Core S&P 500 ETF Vanguard S&P 500 ETF Vanguard Total Stock Market ETF Invesco QQQ Trust Series I Vanguard FTSE Developed Markets ETF Vanguard Value ETF Vanguard Total Bond Market ETF iShares Core MSCI EAFE ETF iShares Core U.S. Aggregate Bond ETF Vanguard Growth ETF iShares Russell 1000 Growth ETF Vanguard FTSE Emerging Markets ETF iShares Core MSCI Emerging Markets ETF iShares Core S&P Mid-Cap ETF Vanguard Dividend Appreciation ETF iShares Core S&P Small-Cap ETF SPDR Gold Shares Vanguard Total International Stock ETF Vanguard Total International Bond ETF Vanguard Mid-Cap ETF Vanguard Information Technology ETF iShares Russell 2000 ETF Technology Select Sector SPDR ETF iShares Russell 1000 Value ETF

    Curated Portfolios (Vests)

    Moat Bitcoin Vest SAAS Multi-Asset Class - Aggressive Multi-Asset Class - Moderate Multi-Asset Class - Conservative Digital Cash Deglobalization Vest BlackRock Smart Beta Aging Vest Swensen Portfolio All Weather

    Others

    Calculators Terms and conditions Privacy Policy Everything Legal
    • 1Top 25 as per Marketwatch
    • 2Top 10 US Stocks from S&P 500 index as per market capitalization
    • 1Total number of KYCed accounts on Vested as of November 2023
    • 2The above portfolio is not meant to represent any real person's portfolio or a suggested portfolio but to show what a typically diversified portfolio might look like
    • 3US Stocks and ETFs are powered by VF Securities, Inc (Member FINRA/SIPC)

    Risk Disclosure - US Markets

    Global

    Vested Finance Inc. is an investment adviser in California. Vested Finance Inc. is registered with the Securities and Exchange Commission (SEC). Registration of an investment adviser dVested Finance Inc. is an investment adviser in California. Vested Finance Inc. is registered with the Securities and Exchange Commission (SEC). Registration of an investment adviser does not imply any specific level of skill or training and does not constitute an endorsement of the firm by the Commission. Vested Finance Inc. only transacts business in states in which it is properly registered or is excluded or exempted from registration. A copy of Vested Finance Inc.’s current written disclosure brochure filed with the SEC which discusses among other things, Vested Finance Inc.’s business practices, services and fees, is available through the SEC’s website at: www.adviserinfo.sec.gov. You can also find a copy of our customer relationship summary (Form CRS) here.

    All securities are offered through VF Securities, Inc. (member FINRA/SIPC). More information about this firm can be found at www.brokercheck.finra.org and at SIPC.org. This website is maintained and published by Vested Finance Inc. Vested Finance Inc., VF Securities Inc., and Vested Private Services Limited are wholly owned subsidiaries of Vested Holding Corp., referred to herein as Vested Group. You can learn more about VF Securities, Inc. on FINRA’s Broker.… Read more

    All investing carries risk. Past performance is not indicative of future returns, which may vary. Investments in stocks and Exchange Traded Funds (“ETFs”) may decline in value. Online trading has inherent risk due to system response and access times that may be affected by various factors, including but not limited to market conditions and system performance. An investor should understand such facts before trading. The risks associated with investing in international securities [including US-listed American Depositary Receipts (“ADRs”) and ETFs that contain non-US securities include, among others, country/political risk relating to the government in the home country; exchange rate risk if the country’s currency is devalued; and inflationary/purchasing power risks if the currency of the home country becomes less valuable as the general level of prices for goods and services rises.

    The information and services provided on this website are not provided to and may not be used by any person or entity in any jurisdiction where the provision or use thereof would be contrary to applicable laws, rules or regulations of any governmental authority or regulatory or self-regulatory organization or where Vested Group is not authorized to provide such information or services.

    All information published on this website is for informational purposes only and no part of it must be construed as an offer to sell or buy a security.

    No information published on the website is intended to be investment advice, portfolio management or as any form of research analysis, directly or indirectly. Each DIY Vest is created by individual users of this website, and Vested Group does not have any role in the selection of stocks for DIY Vests. The users of the website shall be solely responsible for any action taken by them pursuant to the information contained herein, including any investment decision with respect to transaction in securities for which a platform is made available on this website.

    Vested Group makes no warranty or representation, either express or implied, on any product or service offered through its website/platform. Vested Group shall not be liable in any manner whatsoever for any damage or loss, whatsoever caused, in connection with the services provided on this website/platform. Hyperlinks or external websites which may be accessed through this website, if any, are for the user’s convenience and Vested Group does not take any responsibility for the same. Any description of, reference to, or links to other products, publications or services does not constitute an endorsement, authorization, solicitation, advertisement, sponsorship by or affiliation with Vested Group with respect to any linked site or its sponsor, unless expressly stated by Vested Group. While reasonable care has been exercised to ensure that the information published on this website is adequate and reliable, no representation is made by Vested Group as to its accuracy, completeness, or fitness for any purpose and Vested Group, its affiliates, subsidiaries, and employees accept no liability of whatsoever nature for any direct or consequential loss, including without limitation any loss of profits, arising from reliance on this information.

    Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investors’ sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor.

    Read less

    Risk Disclosure - Indian Markets

    india

    P2P lending and INR Bonds are offered through Vested Services Private Limited. Such investments are subject to risks including loss of principal.

    If you have any questions about this disclaimer or in relation to information and services provided through this website, please contact us at help@vestedfinance.co / +919513375607 while providing your contact details for us to correspond further, if required. We welcome your questions and suggestions about us.

     

    By using our website, you agree to our terms and privacy policy.

    Scroll to Top